SYNCOMF2023-04-012023-06-30 SYNCOMF2023-04-012023-06-30in-bse-fin:OneOperatingExpenses01Member SYNCOMF2023-06-30 SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue01Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue02Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentRevenue03Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults01Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults02Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentResults03Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets01Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets02Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentAssets03Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2023-06-30in-bse-fin:OneReportableSegmentLiabilities01Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2023-06-30in-bse-fin:OneReportableSegmentLiabilities02Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2023-06-30in-bse-fin:OneReportableSegmentLiabilities03Member SYNCOMF2023-04-012023-06-30in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524470 SYNCOMF NOTLISTED Syncom Formulations (India) Limited Equity 2023-04-01 2024-03-31 2023-08-14 2023-08-03 INR Lakhs First quarter 11:00:00 14:15:00 2023-08-14 2023-08-14 Not applicable Multi segment 2023-04-01 2023-06-30 Unaudited Consolidated 598358000.00 18747000.00 617105000.00 226531000.00 92142000.00 36822000.00 76281000.00 11217000.00 11000000.00 101985000.00 555978000.00 61127000.00 0.00 61127000.00 17545000.00 -381000.00 17164000.00 0.00 43963000.00 0.00 0.00 0.00 0.00 43963000.00 20677000.00 64640000.00 0.00 0.00 940000000.00 1 0.07 0.07 0.00 0.00 0.07 0.07 Other expenses 101985000.00 Pharmaceuticals Drugs & Commodities 560659000.00 Renting of Property 10748000.00 Trading of Commodites 45698000.00 617105000.00 0.00 617105000.00 Pharmaceuticals Drugs & Commodities 62621000.00 Renting of Property 10293000.00 Trading of Commodites -570000.00 72344000.00 11217000.00 0.00 1. The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 14/08/2023 2. These above results have been prepared in compliance with the Indian Accounting Standard (referred to as Ind AS ) as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time. 3. The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required. 4. As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June 2023. The report does not have any impact on the above results and notes which needs explanation. 5. Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification. 6. The company has The company has generated Rs. 1035.76 Lakhs being the upfront amount and Rs. 2995.74 Lakhs by conversion of 15,93,47,820 warrants to 15,93,47,820 equity shares of Rs. 1/- each issued at a premium of Rs. 1.53 per share aggregating Rs. 4031.50 Lakhs. Out of which the company has already utilized the amount of Rs. 3446.33 Lakhs (Including capital work in progress), Remaining unutilized amount of Rs. 585.17 Lakhs will be used in the subsequent period. Trial Production has been started from 30th June 2023 and commercial Production will be started by end of Aug.23 . There is no deviation in the project till 30th June, 2023 and necessary report towards as required under regulation 32 being filed to the BSE Ltd. Separately 7. The Company has incorporated 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd. and Sante Biotech Pvt. Ltd. on 21st July, 2022 and Vincit Biotech International Pvt. Ltd. on 25th July, 2022 .The Subsidiary Companies have obtained Drug Licenses and other approvals from the Competent Authorities, during the Quarter under review, these Subsidiary Companies were Business Activities 8. The Company is not having any subsidiary Company as on 30/06/2022. The Company has provided Standalone figures for 30/06/2022 for compariing the same with 30/06/2023 on consolidated basis 61127000.00 Pharmaceuticals Drugs & Commodities 3208585000.00 Renting of Property 473345000.00 Trading of Commodites 98014000.00 3779944000.00 0.00 3779944000.00 Pharmaceuticals Drugs & Commodities 1112746000.00 Renting of Property 16356000.00 Trading of Commodites 26049000.00 1155151000.00 0.00 1155151000.00 IND- AS Adjustments 20677000.00 20677000.00 0.00